These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18611560)

  • 1. Strategies for the treatment and prevention of cytomegalovirus infections.
    Neyts J; De Clercq E
    Int J Antimicrob Agents; 1993; 3(3):187-204. PubMed ID: 18611560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    McGavin JK; Goa KL
    Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones CJ; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ; Wirin D; Shaked A; Busuttil RW
    Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
    Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
    Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infections in heart and heart-lung transplant recipients.
    Wreghitt T
    J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H; Kanz L; Jahn G; Einsele H
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
    Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
    Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
    Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis.
    Boivin G; Erice A; Crane DD; Dunn DL; Balfour HH
    J Infect Dis; 1993 Aug; 168(2):332-5. PubMed ID: 8393055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
    Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
    Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of cytomegalovirus infections in renal transplants].
    Rondeau E; Peraldi MN; Kanfer A; Sraer JD
    Nephrologie; 1991; 12(4):189-92. PubMed ID: 1660570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
    Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.